Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This study found that UV-B exposure significantly increased the expression of inflammatory cytokines IL-1β and IL-8 in cultured sebocytes.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This study concluded that Aloe vera fermentation significantly accelerates burn injury healing in rats by reducing inflammation and altering gut microbiota composition.

This study found that a newly synthesized peptide from fermented Trapa japonica extract significantly promoted wound recovery and showed antiaging effects in skin cells and a clinical study, suggesting potential as a cosmetic product.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

This systematic review identified several factors contributing to increased cardiovascular risk in women with polycystic ovary syndrome, including insulin resistance, obesity, inflammation markers, and microbiota alterations linked to elevated trimethylamine-N-oxide levels.

In this study, subcutaneous injection of bone marrow mesenchymal stem cells in burned rats significantly improved wound healing by reducing inflammation, scar formation, and wound size, and restoring normal skin structures.

This case report describes a patient who developed multiple skin reactions, including eczematous lesions and alopecia areata, during adalimumab treatment, but found no improvement in pustulosis palmoplantaris with different biologics.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

In this study, successful treatment outcomes with platelet-rich plasma injections in patients with IC/BPS and rUTI were associated with specific cytokine concentrations, particularly lower TNF-α levels.

This review reports no new results but highlights the secretory function of keratinocytes, focusing on how various secretions, notably growth factors, impact stem cell differentiation into keratinocytes.

This study found that higher levels of DHA from omega-3 fatty acids delayed inflammation resolution and impaired wound healing quality in both transgenic mice and wild-type mice supplemented with DHA.

This case report highlights a potential association between etanercept, a TNF-α blocker, and the onset of alopecia areata, suggesting complex interactions between anti-TNF-α treatments and hair follicle growth.

This study in an animal model found that Rigenera® technology's use of autologous micrografts improved wound healing in diabetic rats by increasing factors like VEGF-A, IL4, and IL10 while reducing TNF-α and oxidative stress.

This study identified a significant genetic association between the TNFα gene and alopecia areata susceptibility in the Jordanian Arab population.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This study found that topical ginsenoside Rg1 may protect skin from UVB-induced damage in mice by reducing pathological changes and modulating cytokine mRNA expression associated with inflammation and immune response.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

This study found that oral pulse steroids significantly reduced serum and tissue levels of TNF-α in patients with alopecia areata, correlating with clinical improvement.

In this study, topical naringin was found to significantly improve dermatitis severity and reduce inflammatory markers in a mouse model of atopic dermatitis, suggesting its potential as a therapeutic agent for this condition.

This study observed that patients with recurrent furunculosis had different cytokine profiles compared to healthy subjects and that retinol stimulation altered cytokine secretion in both groups.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study investigated single-cell changes in photoaged skin, revealing distinct cell clusters and increased activity in PD-L1 and PD-1 pathways in sun-exposed areas, enhancing understanding of UVA-induced skin damage and potential prevention targets for photoaging and UV-induced skin cancers.

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.